

AT₂ (N-19): sc-7421

BACKGROUND

Angiotensin II (Ang II) is an important physiological effector of blood pressure and volume regulation through vasoconstriction, aldosterone release, sodium uptake and thirst stimulation. Although Ang II interacts with two types of cell surface receptors, AT₁ and AT₂, most of the major cardiovascular effects seem to be mediated through AT₁. Molecular cloning of the AT₁ protein has shown it to be a member of the G protein-associated seven transmembrane protein receptor family. Ang II treatment of cells results in activation of several signal transduction pathways as evidenced by tyrosine phosphorylation of several proteins and induction of others. PLC γ is phosphorylated after 30 seconds of treatment with Angiotensin II, indicating this as an early signal transduction event. Ang II treatment also stimulates phosphorylation of Shc, FAK and MAP kinases, and induces MKP-1, indicating stimulation of growth factor pathways. Ang II stimulation through AT₁ has been shown to activate the JAK/Stat pathway involving a direct interaction between JAK2 and AT₁ as demonstrated by coimmunoprecipitation. The AT₁ receptor has no cytoplasmic kinase domain, but is able to function as a substrate for Src kinases and has several putative phosphorylation sites.

CHROMOSOMAL LOCATION

Genetic locus: AGTR2 (human) mapping to Xq23.

SOURCE

AT₂ (N-19) is an affinity purified goat polyclonal antibody raised against a peptide mapping within an N-terminal extracellular domain of AT₂ of human origin.

PRODUCT

Each vial contains 200 μ g IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-7421 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

AT₂ (N-19) is recommended for detection of AT₂ of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 μ g per 100-500 μ g of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500), immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for AT₂ siRNA (h): sc-29752, AT₂ shRNA Plasmid (h): sc-29752-SH and AT₂ shRNA (h) Lentiviral Particles: sc-29752-V.

Molecular Weight (predicted) of AT₂: 41 kDa.

Molecular Weight (observed) of AT₂: 50 kDa.

Positive Controls: Hep G2 cell lysate: sc-2227.


RESEARCH USE

For research use only, not for use in diagnostic procedures.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

DATA



AT₂ (N-19): sc-7421. Immunoperoxidase staining of formalin fixed, paraffin-embedded human prostate tissue showing cytoplasmic staining of glandular cells.

SELECT PRODUCT CITATIONS

- Dominguez-Jimenez, C., et al. 2001. Involvement of α 3 Integrin/tetraspanin complexes in the angiogenic response induced by Angiotensin II. *FASEB J.* 15: 1457-1459.
- Nouet, S., et al. 2004. *Trans*-inactivation of receptor tyrosine kinases by novel angiotensin II AT₂ receptor-interacting protein, ATIP. *J. Biol. Chem.* 279: 28989-28997.
- Woost, P.G., et al. 2007. Development of an AT₂-deficient proximal tubule cell line for transport studies. *In vitro Cell. Dev. Biol. Anim.* 43: 352-360.
- Sendra, J., et al. 2008. Angiotensin II upregulates LDL receptor-related protein (LRP1) expression in the vascular wall: a new pro-atherogenic mechanism of hypertension. *Cardiovasc. Res.* 78: 581-589.
- Johansson, M.E., et al. 2008. Angiotensin type 2 receptor is expressed in human atherosclerotic lesions. *J. Renin Angiotensin Aldosterone Syst.* 9: 17-21.
- Striker, G.E., et al. 2008. Regulation of Angiotensin II receptors and extracellular matrix turnover in human retinal pigment epithelium: role of Angiotensin II. *Am. J. Physiol., Cell Physiol.* 295: C1633-C1646.
- Spak, E., et al. 2008. Angiotensin II-induced contractions in human jejunal wall musculature *in vitro*. *Acta Physiol.* 193: 181-190.
- Song, R., et al. 2010. Angiotensin II AT₂ receptor regulates ureteric bud morphogenesis. *Am. J. Physiol. Renal Physiol.* 298: F807-F817.
- Tower, C.L., et al. 2010. Differential expression of angiotensin II type 1 and type 2 receptors at the maternal-fetal interface: potential roles in early placental development. *Reproduction* 140: 931-942.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.